Amman, Oct. 11 (Petra) — Director General of the Jordan Food and
Drug Administration (JFDA) Rana Obeidat affirmed Sunday that Jordan
remains a regional pioneer in pharmaceutical studies, backed by
advanced legislative frameworks that enhance the national sector’s
competitiveness regionally and internationally.

Speaking at the opening of a training workshop titled “The
Pharmaceutical Studies Law and Instructions for Conducting Clinical
Trials,” organized by the ACDIMA Center for Bioequivalence and
Pharmaceutical Studies in cooperation with the JFDA and the Jordanian
Association of Pharmaceutical Manufacturers (JAPM), Obeidat announced
that the administration will soon unveil the key themes of its
upcoming international conference on advancing pharmaceutical
research. She emphasized that clinical trials and bioequivalence
studies form a fundamental pillar for innovation, scientific
research, and verifying drug safety, efficacy, and quality.

Secretary-General of the JAPM Hanan Al-Sboul highlighted Jordan’s
accumulated expertise and qualified human resources in pharmaceutical
research. She stressed that public-private partnerships among the
JFDA, academic centers, research institutes, and drug manufacturers
continue to drive national innovation and sector growth.

The workshop included a panel discussion on the regulatory landscape
governing pharmaceutical trials. Head of the JFDA Pharmaceutical
Studies Department, Rima Atoum, detailed legal requirements, Good
Clinical Practice (GCP) guidelines, and stakeholder responsibilities,
including ethics committees and principal investigators.

Additionally, Head of the Narcotics and Psychotropic Substances
Department outlined regulatory controls governing the possession,
licensing, storage, and handling of controlled substances utilized in
clinical research.

A second session focused on maintaining sector leadership and
enhancing the capabilities of local research centers through proposed
strategic recommendations.

//Petra// AF